Approximately 50% of acute intestinal failure (AIF) patients on short-term parenteral nutrition (PN) have intestinal failure-associated liver disease (IFALD) without effect on hospital length of stay and mortality

• Published in: Clinical nutrition ESPEN Vol. 61; pp. 140 - 144
• Main Authors: Cheang, Lai Ye, Chong, Ngian Choo Janet, Poh, Bee Yen, Tan, Lee Boo, Goh, Jia Ling Rachel, Lee, Miaw Sim, Tan, Kim Chye Travis, Kadir, Hanis Abdul, Cheah, Chang Chuen Mark, Salazar, Ennaliza
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.06.2024
• Subjects: Adult; adults; Aged; clinical nutrition; cohort studies; Cross-Sectional Studies; death; diabetes; Female; Gastroenterology and Hepatology; Hospital Mortality; hospitals; Humans; Incidence; Internal Medicine; Intestinal failure; Intestinal Failure - therapy; intestines; Length of Stay; liver diseases; Liver Diseases - epidemiology; Liver Diseases - mortality; liver function; Liver Function Tests; Male; males; Middle Aged; mortality; parenteral feeding; Parenteral Nutrition; patients; Retrospective Studies; risk; Risk Factors; Total parenteral nutrition; Liver function tests; Total parenteral nutrition; Intestinal failure; total parenteral nutrition; liver function tests; intestinal failure
• ISSN: 2405-4577; 2405-4577
• DOI: 10.1016/j.clnesp.2024.03.008

Patients with intestinal failure (IF) are often dependent on PN for provision of calories and nutrients for survival. Similar to chronic intestinal failure (CIF) patients, those who have AIF are also at risk of IFALD, which is a poorly understood but potentially fatal condition. The local incidence of IFALD amongst AIF patients is not known. The primary objective of this study was to determine the incidence of IFALD in AIF patients on short-term PN. Secondary objectives were to analyse patient and PN risk factors of IFALD, and clinical outcomes of length of stay (LOS) and inpatient mortality. This was a retrospective cross-sectional cohort study of hospitalised adult patients with AIF prescribed with short-term PN. All adult patients aged 21 years and above who received PN for at least 5 consecutive days and had normal liver function tests (LFTs) at the time of PN initiation were included in this study. A total of 171 patients were enrolled in this study, with 77 (45%) having deranged LFTs at the end of PN therapy and categorised under the IFLAD group. The patient cohort was predominantly male (92 [54%]) and had a median age of 68 years (IQR 59–76). Patients with IFALD at the end of PN therapy had higher diabetes prevalence (36% vs 26%, p = 0.2) and were on PN for a longer duration (median [IQR]: 12 [8–17] vs 8 [6–15] days, p = 0.003) than those without IFALD. There were no significant differences in patient and PN characteristics between the IFLAD and non-IFALD group. The multivariable models showed that the IFALD cohort had longer hospital stays (HR 0.90, 95% CI 0.65–1.23) and lower odds of inpatient death (OR 0.75, 95% CI 0.12–4.60), though both findings are not statistically significant (p = 0.5, 0.7). In this study, IFALD is a common phenomenon in AIF and the incidence was found to be an estimated 50% amongst patients on short-term PN with similar clinical outcomes between the two groups.